Dialysis Solutions
In clinical developmentAlso known as Dialysate, Dialysis fluid.
Recent clinical, regulatory, research and industry developments relating to this drug.
Renal Association Clinical Practice Guideline on Haemodialysis.
Biological Effects of Citrate-buffered Solutions on Dialysis Efficiency and Systemic Inflammation
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- BMC nephrology1
- Andrea Fox RN1
- Ashby D1
- Borman N1
- Burton J1
- Corbett R1
- Davenport A1
- Farrington K1
- Flowers K1
- Great Ormond Street Hospital1
- Hammersmith Hospital1
- King's College Hospital1
- Leeds Teaching Hospitals NHS Trust1
- Lister Hospital1
- Nottingham University Hospitals NHS Trust1
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials